Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States

por Ma, Xiaomei, Steensma, David P, Scott, Bart L, Kiselev, Pavel, Sugrue, Mary M, Swern, Arlene S
Publicado 2018

Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy

por Zimmerman, Zachary, Scott, Bart L., Gopal, Ajay K., Sandmaier, Brenda M., Maloney, David G., Deeg, H. Joachim
Publicado 2011

Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferativ...

por Monaco, Federico, Scott, Bart L., Chauncey, Thomas R., Petersen, Finn B., Storer, Barry E., Baron, Frederic, Flowers, Mary E., Deeg, H. Joachim, Maloney, David G., Storb, Rainer, Sandmaier, Brenda M.
Publicado 2019

Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia

por Woo, Janghee, Choi, Dae Ro, Storer, Barry E., Yeung, Cecilia, Halpern, Anna B., Salit, Rachel B., Sorror, Mohamed L., Woolston, David W., Monahan, Tim, Scott, Bart L., Deeg, H. Joachim
Publicado 2020

CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes

por de Lima, Marcos, Oran, Betul, Champlin, Richard E., Papadopoulos, Esperanza B., Giralt, Sergio A., Scott, Bart L., William, Basem M., Hetzer, Joel, Laille, Eric, Hubbell, Becky, Skikne, Barry S., Craddock, Charles
Publicado 2018

High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative A...

por Gagelmann, Nico, Salit, Rachel B., Schroeder, Thomas, Badbaran, Anita, Rautenberg, Christina, Panagiota, Victoria, Wolschke, Christine, Thol, Felicitas, Cassinat, Bruno, Robin, Marie, Heuser, Michael, Reinhardt, Hans Christian, Scott, Bart L., Kröger, Nicolaus
Publicado 2022

Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome

por Gerds, Aaron T., Scott, Bart L., Greenberg, Peter, Lin, Tara L., Pollyea, Daniel A., Verma, Amit, Dail, Monique, Feng, Yuning, Green, Cherie, Ma, Connie, Medeiros, Bruno C., Yan, Mark, Yousefi, Kasra, Donnellan, William
Publicado 2022

Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis

por Gagelmann, Nico, Wolschke, Christine, Salit, Rachel B., Schroeder, Thomas, Ditschkowski, Markus, Panagiota, Victoria, Cassinat, Bruno, Thol, Felicitas, Badbaran, Anita, Robin, Marie, Reinhardt, Hans Christian, Ayuk, Francis, Heuser, Michael, Scott, Bart L., Kröger, Nicolaus
Publicado 2022

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia

por Verstovsek, Srdan, Mesa, Ruben, Talpaz, Moshe, Kiladjian, Jean-Jacques, Harrison, Claire N., Oh, Stephen T., Vannucchi, Alessandro M., Rampal, Raajit, Scott, Bart L., Buckley, Sarah A., Craig, Adam R., Roman-Torres, Karisse, Mascarenhas, John O.
Publicado 2021

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

por Maziarz, Richard T., Levis, Mark, Patnaik, Mrinal M., Scott, Bart L., Mohan, Sanjay R., Deol, Abhinav, Rowley, Scott D., Kim, Dennis D. H., Hernandez, Daniela, Rajkhowa, Trivikram, Haines, Kelly, Bonifacio, Gaetano, Rine, Patrice, Purkayastha, Das, Fernandez, Hugo F.
Publicado 2020

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neo...

por Halpern, Anna B., Othus, Megan, Huebner, Emily M., Buckley, Sarah A., Pogosova-Agadjanyan, Era L., Orlowski, Kaysey F., Scott, Bart L., Becker, Pamela S., Hendrie, Paul C., Chen, Tara L., Percival, Mary-Elizabeth M., Estey, Elihu H., Stirewalt, Derek L., Walter, Roland B.
Publicado 2017

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis

por Oh, Stephen T., Mesa, Ruben A., Harrison, Claire N., Bose, Prithviraj, Gerds, Aaron T., Gupta, Vikas, Scott, Bart L., Kiladjian, Jean-Jacques, Lucchesi, Alessandro, Kong, Tim, Buckley, Sarah A., Tyavanagimatt, Shanthakumar, Harder, Bryan G., Roman-Torres, Karisse, Smith, Jennifer, Craig, Adam R., Mascarenhas, John, Verstovsek, Srdan
Publicado 2023

Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms

por Halpern, Anna B., Othus, Megan, Huebner, Emily M., Scott, Bart L., Becker, Pamela S., Percival, Mary-Elizabeth M., Hendrie, Paul C., Gardner, Kelda M., Chen, Tara L., Buckley, Sarah A., Orlowski, Kaysey F., Anwar, Asma, Appelbaum, Frederick R., Erba, Harry P., Estey, Elihu H., Walter, Roland B.
Publicado 2018

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML

por Halpern, Anna B., Rodríguez-Arbolí, Eduardo, Othus, Megan, Garcia, Kelsey-Leigh A., Percival, Mary-Elizabeth M., Cassaday, Ryan D., Oehler, Vivian G., Becker, Pamela S., Appelbaum, Jacob S., Abkowitz, Janis L., Orozco, Johnnie J., Keel, Siobán B., Hendrie, Paul C., Scott, Bart L., Ghiuzeli, M. Cristina, Estey, Elihu H., Walter, Roland B.
Publicado 2023

Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome

por Dillon, Laura W., Gui, Gege, Logan, Brent R., Fei, Mingwei, Ghannam, Jack, Li, Yuesheng, Licon, Abel, Alyea, Edwin P., Bashey, Asad, Devine, Steven M., Fernandez, Hugo F., Giralt, Sergio, Hamadani, Mehdi, Howard, Alan, Maziarz, Richard T., Porter, David L., Warlick, Erica D., Pasquini, Marcelo C., Scott, Bart L., Horwitz, Mitchell E., Deeg, H. Joachim, Hourigan, Christopher S.
Publicado 2021

Real‐world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower‐risk myelodysplastic syndromes

por Patel, Jay L., Abedi, Mehrdad, Cogle, Christopher R., Erba, Harry P., Foucar, Kathryn, Garcia‐Manero, Guillermo, Grinblatt, David L., Komrokji, Rami S., Kurtin, Sandra E., Maciejewski, Jaroslaw P., Pollyea, Daniel A., Revicki, Dennis A., Roboz, Gail J., Savona, Michael R., Scott, Bart L., Sekeres, Mikkael A., Steensma, David P., Thompson, Michael A., Dawn Flick, Elizabeth, Kiselev, Pavel, Louis, Chrystal U., Nifenecker, Melissa, Swern, Arlene S., George, Tracy I.
Publicado 2020

Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect(®) MDS/AML Disease Registry

por Pollyea, Daniel A., George, Tracy I., Abedi, Mehrdad, Bejar, Rafael, Cogle, Christopher R., Foucar, Kathryn, Garcia‐Manero, Guillermo, Grinblatt, David L., Komrokji, Rami S., Maciejewski, Jaroslaw P., Revicki, Dennis A., Roboz, Gail J., Savona, Michael R., Scott, Bart L., Sekeres, Mikkael A., Thompson, Michael A., Kurtin, Sandra E., Louis, Chrystal U., Nifenecker, Melissa, Flick, E. Dawn, Swern, Arlene S., Kiselev, Pavel, Steensma, David P., Erba, Harry P.
Publicado 2020

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades

por Cooper, Jason P., Storer, Barry E., Granot, Noa, Gyurkocza, Boglarka, Sorror, Mohamed L., Chauncey, Thomas R., Shizuru, Judith, Franke, Georg-Nikolaus, Maris, Michael B., Boyer, Michael, Bruno, Benedetto, Sahebi, Firoozeh, Langston, Amelia A., Hari, Parameswaran, Agura, Edward D., Petersen, Søren Lykke, Maziarz, Richard T., Bethge, Wolfgang, Asch, Julie, Gutman, Jonathan A., Olesen, Gitte, Yeager, Andrew M., Hübel, Kai, Hogan, William J., Maloney, David G., Mielcarek, Marco, Martin, Paul J., Flowers, Mary E. D., Georges, George E., Woolfrey, Ann E., Deeg, H. Joachim, Scott, Bart L., McDonald, George B., Storb, Rainer, Sandmaier, Brenda M.
Publicado 2020

The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation...

por Mei, Matthew, Pillai, Raju, Kim, Soyoung, Estrada-Merly, Noel, Afkhami, Michelle, Yang, Lixin, Meng, Zhuo, Abid, Muhammad Bilal, Aljurf, Mahmoud, Bacher, Ulrike, Beitinjaneh, Amer, Bredeson, Christopher, Cahn, Jean-Yves, Cerny, Jan, Copelan, Edward, Cutler, Corey, DeFilipp, Zachariah, Perez, Miguel Angel Diaz, Farhadfar, Nosha, Freytes, César O., Gadalla, Shahinaz M., Ganguly, Siddhartha, Gale, Robert Peter, Gergis, Usama, Grunwald, Michael R., Hamilton, Betty K., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Lazarus, Hillard M., Litzow, Mark, Munker, Reinhold, Murthy, Hemant S., Nathan, Sunita, Nishihori, Taiga, Patel, Sagar S., Rizzieri, David, Seo, Sachiko, Shah, Mithun Vinod, Solh, Melhem, Verdonck, Leo F., Vij, Ravi, Sobecks, Ronald M., Oran, Betul, Scott, Bart L., Saber, Wael, Nakamura, Ryotaro
Publicado 2022

A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

por Tamari, Roni, McLornan, Donal P., Ahn, Kwang Woo, Estrada-Merly, Noel, Hernández-Boluda, Juan Carlos, Giralt, Sergio, Palmer, Jeanne, Gale, Robert Peter, DeFilipp, Zachariah, Marks, David I., van der Poel, Marjolein, Verdonck, Leo F., Battiwalla, Minoo, Diaz, Miguel Angel, Gupta, Vikas, Ali, Haris, Litzow, Mark Robert, Lazarus, Hillard M., Gergis, Usama, Bashey, Asad, Liesveld, Jane, Hashmi, Shahrukh, Pu, Jeffrey J., Beitinjaneh, Amer, Bredeson, Christopher, Rizzieri, David, Savani, Bipin N., Abid, Muhammad Bilal, Ganguly, Siddhartha, Agrawal, Vaibhav, Ulrike Bacher, Vera, Wirk, Baldeep, Jain, Tania, Cutler, Corey, Aljurf, Mahmoud, Kindwall-Keller, Tamila, Kharfan-Dabaja, Mohamed A., Hildebrandt, Gerhard C., Pawarode, Attaphol, Solh, Melhem M., Yared, Jean A., Grunwald, Michael R., Nathan, Sunita, Nishihori, Taiga, Seo, Sachiko, Scott, Bart L., Nakamura, Ryotaro, Oran, Betul, Czerw, Tomasz, Yakoub-Agha, Ibrahim, Saber, Wael
Publicado 2023